|drug110||ASC09/ritonavir group Wiki||1.00|
|drug3914||lopinavir/ritonavir group Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
To obtain more knowledge about the generation of aerosol and droplet dispersion and deposition during naso-gastric intubation for gastrointestinal motility investigations
Description: Visualization of the number of droplets using a UV-lamp (wood lamp) to detect the spread of droplets.Measure: Number of droplets spread on the investigator and their location on gown or goggles, by the end of the procedure of naso-gastric intubation for gastrointestinal motility investigations. Time: After the motility investigation (within 1 hour)
Description: Measurement of the aerosol particles in the room during motility investigations.Measure: Generation of aerosol particles by insertion and by removal of the naso-gastric motility or pH monitoring probe. Time: Before placement of the probe (1 and 5 minutes) and after the removement of the probe (1 and 5 minutes).
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports